__NUXT_JSONP__("/drugs/Inebilizumab", (function(a,b,c,d,e){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:b,indication:c,manufacturer:"Viela Bio, Inc.",splSetId:"0ce5e7f6-eb97-4738-8b10-43b89e16b5b3"},{brand:b,indication:c,manufacturer:"Horizon Therapeutics USA, Inc.",splSetId:"834db232-afb0-4dcf-93e0-009ce8245c20"}],id:a,nciThesaurus:{casRegistry:"1299440-37-1",chebiId:d,chemicalFormula:d,definition:"A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.",fdaUniiCode:"74T7185BMM",identifier:"C88283",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C112889"],synonyms:["INEBILIZUMAB",a,"MEDI-551"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FInebilizumab",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("Inebilizumab","UPLIZNA","1 INDICATIONS AND USAGE UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1 )","","2021-10-30T13:46:47.423Z")));